292 related articles for article (PubMed ID: 18173821)
1. Evolution of transdermal oxybutynin in the treatment of overactive bladder.
Sahai A; Mallina R; Dowson C; Larner T; Khan MS
Int J Clin Pract; 2008 Jan; 62(1):167-70. PubMed ID: 18173821
[TBL] [Abstract][Full Text] [Related]
2. Transdermal oxybutynin for overactive bladder.
Davila GW; Starkman JS; Dmochowski RR
Urol Clin North Am; 2006 Nov; 33(4):455-63, viii. PubMed ID: 17011381
[TBL] [Abstract][Full Text] [Related]
3. Transdermal oxybutynin: sticking to the facts.
Cartwright R; Cardozo L
Eur Urol; 2007 Apr; 51(4):907-14; discussion 914. PubMed ID: 17157979
[TBL] [Abstract][Full Text] [Related]
4. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study.
Sand P; Zinner N; Newman D; Lucente V; Dmochowski R; Kelleher C; Dahl NV
BJU Int; 2007 Apr; 99(4):836-44. PubMed ID: 17187655
[TBL] [Abstract][Full Text] [Related]
5. Oxybutynin gel for the treatment of overactive bladder.
Gomelsky A; Dmochowski RR
Expert Opin Pharmacother; 2012 Jun; 13(9):1337-43. PubMed ID: 22607010
[TBL] [Abstract][Full Text] [Related]
6. Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder.
Staskin DR; Robinson D
Expert Opin Pharmacother; 2009 Dec; 10(18):3103-11. PubMed ID: 19954278
[TBL] [Abstract][Full Text] [Related]
7. Transdermal drug delivery treatment for overactive bladder.
Dmochowski RR; Starkman JS; Davila GW
Int Braz J Urol; 2006; 32(5):513-20. PubMed ID: 17081319
[TBL] [Abstract][Full Text] [Related]
8. Transdermally-delivered oxybutynin (Oxytrol(R) for overactive bladder.
Ho C
Issues Emerg Health Technol; 2001 Oct; (24):1-4. PubMed ID: 11776281
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study.
Staskin DR; Dmochowski RR; Sand PK; Macdiarmid SA; Caramelli KE; Thomas H; Hoel G
J Urol; 2009 Apr; 181(4):1764-72. PubMed ID: 19233423
[TBL] [Abstract][Full Text] [Related]
10. Oxybutynin topical and transdermal formulations: an update.
Staskin DR; Salvatore S
Drugs Today (Barc); 2010 Jun; 46(6):417-25. PubMed ID: 20571610
[TBL] [Abstract][Full Text] [Related]
11. The MATRIX study: evaluating the data in older adults.
Newman DK
Director; 2008; 16(3):15-9. PubMed ID: 19343887
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity.
Cartwright PC; Coplen DE; Kogan BA; Volinn W; Finan E; Hoel G
J Urol; 2009 Oct; 182(4):1548-54. PubMed ID: 19683731
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study.
Kennelly MJ; Lemack GE; Foote JE; Trop CS
Urology; 2009 Oct; 74(4):741-5. PubMed ID: 19628264
[TBL] [Abstract][Full Text] [Related]
14. Maximizing anticholinergic therapy for overactive bladder: has the ceiling been reached?
MacDiarmid SA
BJU Int; 2007 Jun; 99 Suppl 3():8-12. PubMed ID: 17488367
[TBL] [Abstract][Full Text] [Related]
15. Patient satisfaction with extended release tolterodine or oxybutynin in overactive bladder.
Bolge SC; McDonnell DD; Chen A; Wan GJ
Curr Med Res Opin; 2007 Aug; 23(8):1903-12. PubMed ID: 17610806
[TBL] [Abstract][Full Text] [Related]
16. Patient-selected goals in overactive bladder: a placebo controlled randomized double-blind trial of transdermal oxybutynin for the treatment of urgency and urge incontinence.
Cartwright R; Srikrishna S; Cardozo L; Robinson D
BJU Int; 2011 Jan; 107(1):70-6. PubMed ID: 20626389
[TBL] [Abstract][Full Text] [Related]
17. The value of oxybutynin in transdermal patches for treating overactive bladder.
Salinas-Casado J; Esteban-Fuertes M; Serrano O; Galván J
Actas Urol Esp; 2015 Dec; 39(10):599-604. PubMed ID: 26321038
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of oxybutynin chloride topical gel for women with overactive bladder syndrome.
Sand PK; Davila GW; Lucente VR; Thomas H; Caramelli KE; Hoel G
Am J Obstet Gynecol; 2012 Feb; 206(2):168.e1-6. PubMed ID: 21963104
[TBL] [Abstract][Full Text] [Related]
19. Muscarinic receptor antagonists for overactive bladder.
Abrams P; Andersson KE
BJU Int; 2007 Nov; 100(5):987-1006. PubMed ID: 17922784
[TBL] [Abstract][Full Text] [Related]
20. Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity: a double-blind, randomized crossover trial.
Fader M; Glickman S; Haggar V; Barton R; Brooks R; Malone-Lee J
J Urol; 2007 Jan; 177(1):208-13; discussion 213. PubMed ID: 17162046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
